Myeloid Sarcoma: Clinical and Morphologic Criteria Useful for Diagnosis

International Journal of Surgical Pathology - Tập 11 Số 4 - Trang 271-282 - 2003
Josée Audouin1, E. Compérat, Agnés Le Tourneau, S. Camilleri-Broët, Colette Adida, Thierry Jo Molina, J Diébold2
1Service “Jacques-Delarue” d'Anatomie et de Cytologie Pathologiques, Hôtel Dieu, Paris, France; Service “Jacques-Delarue” d'Anatomie et de Cytologie Pathologiques, Hôtel Dieu, 1 place du Parvis Notre Dame, 75181 Paris, Cedex 04, France
2Service “Jacques-Delarue” d'Anatomie et de Cytologie Pathologiques, Hôtel Dieu, Paris, France

Tóm tắt

Extramedullary accumulation of myeloblasts or immature myeloid cells form tumors called myeloid sarcoma in the WHO classification. Such tumors develop in lymphoid organs, bone (skull, orbit, etc.), skin, soft tissue, various mucosae and organs, and the CNS. They may precede or occur concurrently with acute myeloid leukemia, or reveal blastic transformation of chronic myeloproliferative disorders or myelodysplastic syndromes. They may also reveal relapses in treated patients. They are constituted by a diffuse infiltrate made up of medium-to-large cells. The cells are difficult to identify. Imprints are very useful. Immunohistochemistry can help diagnose and distinguish four variants: granulocytic myeloperoxidase (MPO+, CD 68+ [KP1, PGM1-] lysozyme+, CD 34), monoblastic (MPO-, CD 68+, [KPI+, PGMI+] lysozyme+, CD 34-), myelomonoblastic (MPO-, CD 68+, [KPI+, PGM1+] lysozyme+, CD 34-), or megakaryoblastic (positivity for factor VIII, CD 61, CD 31). Immunohistochemistry sometimes demonstrates expression of CD 43, CD 7, CD 79a, and CD 56 (particularly the monoblastic variant with t[8;2 1]). Recently the demonstration of CD 99 and CD 1 7, which can now be done on paraffin sections, may be useful to identify blasts of granulocytic origin. The diagnosis is missed in about 50% of cases when immunohistochemistry is not used. Patients with myeloid sarcomas should be treated in the same way as patients with acute myeloblastic leukemia. Disease progression and prognosis are similar for the two conditions.

Từ khóa


Tài liệu tham khảo

Jaffe ES, 2001, Pathology and genetics of tumors of haematopoietic and lymphoid tissues, 104

10.1002/1097-0142(19810915)48:6<1426::AID-CNCR2820480626>3.0.CO;2-G

10.3109/10428190109097737

10.1002/1097-0142(19940415)73:8<2107::AID-CNCR2820730815>3.0.CO;2-W

10.1093/ajcp/107.2.177

10.1097/00000478-199710000-00005

Billio A, 2002, Haematologica, 87, EIMO1

Ponzoni M, 2002, Haematologica, 87, ECRO9

10.3109/10428190009148412

10.1136/bjo.81.12.1084

10.1159/000027279

10.1080/00313020126312

10.1046/j.1442-200X.2001.01437.x

10.1016/S0145-2126(01)00068-6

Hancock JC, 1997, Arch Pathol Lab Med, 121, 520

10.1016/S0145-2126(96)00054-9

Bekassy AN, 1996, Bone Marrow Transplant, 17, 801

10.1002/(SICI)1097-0142(19990201)85:3<608::AID-CNCR11>3.0.CO;2-5

10.1007/s00277-001-0411-x

10.1007/s002770050350

10.1002/cncr.10399

10.1046/j.1365-2559.2001.1301f.x

10.5858/2002-126-0085-CIIGS

10.1046/j.0902-4441.2001.492umedoc.492.x

10.1309/WWW7-DG6X-HC16-D7J2

10.1093/ajcp/104.4.431

10.1038/modpathol.3880077

10.1111/j.1365-2133.2000.03714.x

Seymour JF, 1994, Leukemia, 8, 823

10.1182/blood.V90.6.2417

10.1136/jcp.49.9.762

10.1007/BF01696563

10.1016/0165-4608(88)90245-2

10.1002/(SICI)1098-2264(200002)27:2<136::AID-GCC4>3.0.CO;2-9

10.1016/S0002-9440(10)63052-0

10.1056/NEJM199309233291302

10.1016/0165-4608(94)90030-2

Ishii E, 1995, Leukemia, 11, 1970

10.1002/(SICI)1098-2264(199711)20:3<253::AID-GCC5>3.0.CO;2-1

10.1111/j.1365-2141.1995.tb05176.x

10.1016/S0145-2126(01)00086-8

10.1002/(SICI)1096-8652(199711)56:3<194::AID-AJH14>3.0.CO;2-B

Vasef MA, 1998, Mod Pathol, 11, 1138

10.1200/JCO.1997.15.2.466

Thông tin
Thông tin xuất bản

International Journal of Surgical Pathology

Tập 11 Số 4

271-282

Thông tin tác giả